Stocktoria
Denali Therapeutics Inc. DNLI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-12-08
Denali Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $108.5M | $48.7M |
| R&D expense | $418.8M | $396.4M | $423.9M | $358.7M | $265.4M |
| Operating income | -$555.3M | -$487.3M | -$196.7M | -$340.7M | -$295.8M |
| Income tax | $102,000 | $68,000 | $30,000 | $21,000 | -$575,000 |
| Net income | -$512.5M | -$422.8M | -$145.2M | -$326.0M | -$290.6M |
| EPS (diluted) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 |
| Operating cash flow | -$412.6M | -$347.7M | -$358.0M | -$244.7M | -$211.4M |
| Free cash flow | -$422.1M | -$363.6M | -$370.9M | -$262.5M | -$219.9M |
| Cash & equivalents | $205.3M | $175.0M | $127.1M | $218.0M | $293.5M |
| Total assets | $1.1B | $1.4B | $1.2B | $1.5B | $1.4B |
| Total liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M |
| Shareholders' equity | $1.0B | $1.2B | $1.0B | $1.0B | $962.3M |
Source: SEC EDGAR filings · CIK 0001714899 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.